@aestheticsgroup
Aesthetics Journal
Aesthetics aestheticsjournal.com
Associations
Data
Survey indicates one in five US women intend to have cosmetic treatment A survey has suggested that one in five women are currently pursuing or intending to have cosmetic treatment. Conducted on behalf of RealSelf by Zeitgeist Research, the survey comprised 5,053 women in the US between 18 and 64 years old. It explored the trends of the US market for beyond-the-counter beauty procedures and the potential for expanding the industry. The results found that of the women surveyed, one in five are currently pursuing or planning to have cosmetic surgery. During the survey, it was also indicated that of 87% of women who were unhappy with at least one area of their body, the trend to seek cosmetic treatment has risen by more than 200%, with these women representing an estimated market of more than $75 billion. Of those who were willing to seek treatment beyond the retail floor, 62% would also consider surgery. The 24% of women who are planning for less invasive treatment represent an estimated market of $12 billion. Another area explored in the survey was motivation, which stated that 65% of women wanted to feel more comfortable with themselves, whilst one third (29%) were also considering cosmetic work due to a milestone life event. “While the total market has previously been calculated by the procedures performed in the past year, we can see that the total addressable market is actually far greater,” said Tom Seery, CEO of RealSelf. “As cosmetic procedures continue to become mainstream, millions of women are overcoming social stigma to pursue cosmetic changes they have been researching, often for years.”
R&D Report
Production at Pringy Aesthetics visit the production site and R&D hub for Allergan’s crosslinked family of hyaluronic acid dermal fillers The Allergan Medical site in Pringy, France, was acquired in 2007. Currently, it houses 240 employees, 33 of which carry out the vital research and development work that has secured Allergan’s place as one of the forerunners in the manufacturing and distribution of dermal fillers. Pringy is what Allergan employees refer to as the ‘centre of excellence’. This is because the site in France works as the base for all of Allergan’s manufacturing and R&D activity for Juvéderm – the company’s diverse range of cross-linked, hyaluronic acid dermal fillers. In its two neighbouring buildings, the site has produced around 28 million syringes
BACN announces new board member The British Association of Cosmetic Nurses (BACN) has announced that former Wigmore Medical chairperson David Hicks will take a position on their board. A pharmacist by profession, Mr Hicks actively supported nurses at Wigmore Medical, and the BACN expressed their delight at his appointment. The move has been announced among several changes currently happening at the BACN, which includes an office move to Bristol. Sharon Bennett, BACN chairperson, said, “He brings with him a pair of safe hands, a wealth of experience, and will strengthen the current committee with his knowledge of our specialist area of medicine and his business acumen.” Current BACN board members supported the move unanimously. Of his new position, Mr Hicks said, “I am honoured to be part of the BACN.”
since 2000. The approach at Pringy is a holistic one. “One of the big strengths we have in Pringy is the proximity of the R&D and manufacturing,” explains senior general director Claudie Allaire. “This proximity provides a great sense of collaboration, reactivity and flexibility.” Inspecting this notion closer, director of engineering Pascal Brice notes that, in fact, three worlds combine together at Pringy, “Here we are manufacturing a medical product, whereas the syringe is a pharmaceutical device, yet the packaging belongs to the luxury industry.” As a pharmaceutical company, Allergan has five plants across the world – in Texas, Costa Rica, Brazil, Ireland and France – and more than 10,000 employees. With the confirmation of an acquisition by Actavis in place, this network is set to expand. A theme of continual expansion is evident in Pringy, where plans are in place to increase capacity and automate processes in order to increase quality control; next year they will introduce a state-of-the-art camera system to inspect syringes. “We will be the first pharmaceutical company to inspect syringes with gel using technology,” says Brice. This type of approach aims to eliminate human error, he says, and it is this approach of careful monitoring and continual development of technologies that puts the manufacturing and development of the Juvéderm range in line with regulatory standards closer to that of the pharmaceutical requirements for prescription-onlymedicines (POMs). The mission at Pringy, emphasises Brice, is to exceed customer expectations and quality control is evidently a key term. “We are proud of our strong commitment to quality which influences everything we do,” says Allaire. “From sourcing our ingredients, to manufacturing through to our suppliers – it’s all designed to deliver the highest quality product possible.”
Reproduced from Aesthetics | Volume 2/Issue 5 - April 2015